Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ:IVVD)

1.156 +0.056 (+5.09%)
Streaming Delayed Price Updated: 9:50 AM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 302,133
Open 1.110
Bid (Size) 1.150 (1,900)
Ask (Size) 1.160 (1,000)
Prev. Close 1.100
Today's Range 1.110 - 1.170
52wk Range 0.4830 - 3.070
Shares Outstanding 109,755,624
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
From Invivyd
Via GlobeNewswire

Performance

YTD
-53.8%
-53.8%
1 Month
-21.4%
-21.4%
3 Month
-32.4%
-32.4%
6 Month
-48.2%
-48.2%
1 Year
+19.6%
+19.6%

More News

Read More
News headline image
Invivyd to Participate in Upcoming Investor Events
From Invivyd
Via GlobeNewswire
News headline image
Invivyd (IVVD) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Topics Artificial Intelligence
Invivyd (NASDAQ:IVVD) Q1 Miss Sends Shares Lower as PEMGARDA Revenue Falls Short and R&D Costs Surge ↗
Via Chartmill
News headline image
Invivyd Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
From Invivyd
Via GlobeNewswire
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
News headline image
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Presentation at the World Vaccine Congress Washington
From Invivyd
Via GlobeNewswire
News headline image
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Via Benzinga
Topics Stocks
News headline image
Invivyd (IVVD) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
News headline image
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention
From Invivyd
Via GlobeNewswire

Frequently Asked Questions

Is Invivyd, Inc. - Common Stock publicly traded?
Yes, Invivyd, Inc. - Common Stock is publicly traded.
What exchange does Invivyd, Inc. - Common Stock trade on?
Invivyd, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Invivyd, Inc. - Common Stock?
The ticker symbol for Invivyd, Inc. - Common Stock is IVVD on the Nasdaq Stock Market
What is the current price of Invivyd, Inc. - Common Stock?
The current price of Invivyd, Inc. - Common Stock is 1.156
When was Invivyd, Inc. - Common Stock last traded?
The last trade of Invivyd, Inc. - Common Stock was at 06/04/26 09:50 AM ET
What is the market capitalization of Invivyd, Inc. - Common Stock?
The market capitalization of Invivyd, Inc. - Common Stock is 126.88M
How many shares of Invivyd, Inc. - Common Stock are outstanding?
Invivyd, Inc. - Common Stock has 127M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.